BioVersys AG

There were six initial public offerings by biopharmaceutical companies on Western stock exchanges during the first quarter of 2025, up from four in the fourth quarter of 2024, but all of the IPOs occu

Biotech initial public offerings in Europe have been as rare as hen’s teeth in the past few years so the news that Swiss antibiotics specialist BioVersys is looking to list has caught the eye. The Bas

With rising interest in inflammation and immunology – likely in response to large deals in the I&I space as much as unmet needs in autoimmune diseases – venture capital investors have put big money in

Coya Therapeutics, Inc. launched the final biopharmaceutical initial public offering in the US in 2022 on 29 December, raising $15.25m from the sale of 3.05 million shares at $5 each, which brought t